Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat
Author:
Affiliation:
1. pRED, Pharma Research & Early Development, DTA Cardiovascular & Metabolism; F. Hoffmann-La Roche AG; Basel; Switzerland
2. pRED, Non-Clinical Safety; F. Hoffmann-La Roche AG; Basel; Switzerland
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12006/fullpdf
Reference37 articles.
1. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association;Skyler;Diabetes Care,2009
2. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial;Dormandy;Lancet,2005
3. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease;Staels;Nat Clin Pract Cardiovasc Med,2008
4. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis;Jun;Lancet,2010
5. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes;Bénardeau;Bioorg Med Chem Lett,2009
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Expression of Wilms-tumor 1 antigen, vimentin and corticotropin releasing factor in human kidney with focal segmental glomerulosclerosis and effect of oxidative stress on these markers in HEK 293 cells;Kidney and Blood Pressure Research;2022-12-16
2. Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative;Frontiers in Medicine;2021-07-06
3. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms;European Journal of Medicinal Chemistry;2021-06
4. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension;The American Journal of Pathology;2018-07
5. Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects;European Journal of Medicinal Chemistry;2018-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3